74 research outputs found
Uterine mullerian adenosarcoma with sarcomatous overgrowth fatal recurrence within two weeks of diagnosis: a case report
Mullerian adenosarcoma with sarcomatous overgrowth (MASO) is a rare variant of uterine sarcomas, associated with postoperative recurrence, metastases and a fatal outcome. The mean age at diagnosis is 54.5 years. A 37-year-old nullipara presented with irregular vaginal bleeding, a normal pelvic examination, and an initially negative ultrasound. Repeat ultrasound one month later revealed an 11-cm heterogeneous pelvic mass. She underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Pathology confirmed uterine MASO. Computed tomography 2 weeks postoperatively showed a huge mass compatible with recurrence. Patient died 2 weeks later. MASO is rarely diagnosed in women in their 4th decade. This case stresses that these aggressive tumors should be considered in the differential of patients with vaginal bleeding and pelvic masses irrespective of their age
RETRACTED ARTICLE: miR-484 suppresses proliferation and epithelial–mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells
Effect of manipulation of primary tumour vascularity on metastasis in an adenocarcinoma model
One explanation for the clinical association between tumour vascularity and probability of metastasis is that increased primary tumour vascularity enhances haematogenous dissemination by offering greater opportunity for tumour cell invasion into the circulation (intravasation). We devised an experimental tumour metastasis model that allowed manipulation of primary tumour vascularity with differential exposure of the primary and metastatic tumour site to angiogenic agents. We used this model to assess the effects of local and systemic increases in the level of the angiogenic agent basic fibroblast growth factor on metastasis. BDIX rats with implanted hind limb K12/TR adenocarcinoma tumours received either intratumoural or systemic, basic fibroblast growth factor or saline infusion. Both intratumoural and systemic basic fibroblast growth factor infusion resulted in significant increases in tumour vascularity, blood flow and growth, but not lung metastasis, compared with saline-infused controls. Raised basic fibroblast growth factor levels and increase in primary tumour vascularity did not increase metastasis. The clinical association between tumour vascularity and metastasis is most likely to arise from a metastatic tumour genotype that links increased tumour vascularity with greater metastatic potential
Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III
HPV genotype distribution and anomalous association of HPV33 to cervical neoplastic lesions in San Luis Potosí, Mexico
Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria
Human papillomavirus in semen and the risk for male infertility: a systematic review and meta-analysis
Human papillomavirus genotyping by Linear Array and Next-Generation Sequencing in cervical samples from Western Mexico
Screening for human papillomavirus: Is urine useful?
Persistent infection with high-risk Human papillomavirus (hr-HPV 16,
18, 31, 33, and 45) is the main risk factor for developing malignant
genital lesions. Screening methods and follow-up schedules for cervical
cancer are well known. A golden standard to screen and monitor men does
not exist yet, because HPV-related, life threatening malignancies in
men are rare. The importance of male HPV screening lies mainly in HPV
vaccination. Young females are the target group for HPV, but men are
considered to be the reservoir for HPV and to have a role in the
perpetuation of the infection in the general population. We looked at
the usefulness of urine as a tool for HPV screening. Pubmed was
searched with the words \u2032HPV\u2032, \u2032Urine,\u2032 and
\u2032HPV-DNA\u2032. The chance of finding HPV-DNA in urine is higher
in men with lesions in the urethra than outside the urethra, and in
women with abnormal cervical cytology. In general, the results of
testing urine for HPV-DNA are better for women than for men, probably
because of the anatomical position of the urethra to the vagina, vulva,
and cervix. In both genders, urine HPV prevalence is higher in HIV pos
patients and in high-risk populations. Urine, to screen asymptomatic
low-risk-profile (wo)men seems less useful because their urine samples
are often inadequate. If urine proves to be the best medium to screen,
a low-risk population remains controversial
Screening for human papillomavirus: Is urine useful?
Persistent infection with high-risk Human papillomavirus (hr-HPV 16,
18, 31, 33, and 45) is the main risk factor for developing malignant
genital lesions. Screening methods and follow-up schedules for cervical
cancer are well known. A golden standard to screen and monitor men does
not exist yet, because HPV-related, life threatening malignancies in
men are rare. The importance of male HPV screening lies mainly in HPV
vaccination. Young females are the target group for HPV, but men are
considered to be the reservoir for HPV and to have a role in the
perpetuation of the infection in the general population. We looked at
the usefulness of urine as a tool for HPV screening. Pubmed was
searched with the words ′HPV′, ′Urine,′ and
′HPV-DNA′. The chance of finding HPV-DNA in urine is higher
in men with lesions in the urethra than outside the urethra, and in
women with abnormal cervical cytology. In general, the results of
testing urine for HPV-DNA are better for women than for men, probably
because of the anatomical position of the urethra to the vagina, vulva,
and cervix. In both genders, urine HPV prevalence is higher in HIV pos
patients and in high-risk populations. Urine, to screen asymptomatic
low-risk-profile (wo)men seems less useful because their urine samples
are often inadequate. If urine proves to be the best medium to screen,
a low-risk population remains controversial
- …